NASDAQ : DMAC
DiaMedica Therapeutics Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 9.52 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 513.37M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 500.97M |
| Enterprise Value | 457.65M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 53.93M |
| Shares Outstanding | 53.93M |
| Shares Change (YoY) | +22.41% |
| Shares Change (QoQ) | +0.19% |
| Owned by Insiders (%) | 46.69% |
| Owned by Institutions (%) | 20.56% |
| Float | 25.30M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 13.07 |
| P/TBV Ratio | 13.07 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 6.72 |
| Quick Ratio | 6.63 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -114.62% |
| Return on Assets (ROA) | -64.12% |
| Return on Invested Capital (ROIC) | -74.31% |
| Return on Capital Employed (ROCE) | -102.13% |
| Weighted Average Cost of Capital (WACC) | 9.40% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.07M |
| Employee Count | 35 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 30,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.94 |
| 52-Week Price Change | +31.59% |
| 50-Day Moving Average | 7.67 |
| 200-Day Moving Average | 7.11 |
| Relative Strength Index (RSI) | 63.45 |
| Average Volume (20 Days) | 215,229 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 5.24M |
| Short Previous Month | 5.58M |
| Short % of Shares Out | 9.72% |
| Short % of Float | 20.72% |
| Short Ratio (days to cover) | 21.79 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -39.23M |
| Pretax Income | -37.51M |
| Net Income | -37.54M |
| EBITDA | -39.17M |
| EBIT | -39.23M |
| Earnings Per Share (EPS) | -$0.72 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 43.50M |
| Total Debt | 185,000 |
| Net Cash | 43.32M |
| Net Cash Per Share | $0.80 |
| Equity (Book Value) | 38.34M |
| Book Value Per Share | 0.71 |
| Working Capital | 37.72M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -31.51M |
| Capital Expenditures | -33,000 |
| Depreciation & Amortization | 52,000 |
| Net Borrowing | -11,000 |
| Free Cash Flow | -31.54M |
| FCF Per Share | -$0.58 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -22.41% |
| Shareholder Yield | -22.41% |
| Earnings Yield | -7.70% |
| FCF Yield | -6.30% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $15.50 |
| Price Target Difference | 66.85% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Nov 15, 2018 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |